| 0.029 0.004 (15.77%) | 04-23 14:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.07 | 1-year : | 0.1 |
| Resists | First : | 0.06 | Second : | 0.09 |
| Pivot price | 0.02  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.02 | MA(20) : | 0.03 |
| MA(100) : | 0.4 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 19.1 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 5.09 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CALA ] has closed below upper band by 41.1%. Bollinger Bands are 97.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 76 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.05 - 0.05 | 0.05 - 0.05 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Mon, 22 Apr 2024
Calithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.com - Defense World
Sun, 14 Apr 2024
Calithera Biosciences (NASDAQ:CALA) Receives New Coverage from Analysts at StockNews.com - Defense World
Tue, 10 Jan 2023
Biotech company Calithera plans its own death. Will others follow? - San Francisco Business Times - The Business Journals
Mon, 09 Jan 2023
Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution - Yahoo Finance
Tue, 01 Nov 2022
Where Will Calithera Biosciences Inc (CALA) Stock Go Next After It Has Fallen 1.53% in a Week? - InvestorsObserver
Wed, 17 Nov 2021
Calithera Biosciences Inc. (NASDAQ: CALA) Terminates Phase 2 KEAPSAKE Study Due Telaglenastat's Lack of ... - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 26.7 (%) |
| Shares Short | 417 (K) |
| Shares Short P.Month | 149 (K) |
| EPS | -7.95 |
| EPS Est Next Qtrly | -0.24 |
| EPS Est This Year | -0.82 |
| EPS Est Next Year | -1.05 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.3 % |
| Return on Equity (ttm) | -114.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|